The month ahead: May’s remaining events
Conference activity picks up, with the big one – ASCO – at the end of the month.
Conference activity picks up, with the big one – ASCO – at the end of the month.
Casdatifan yields its first median PFS number, but Gilead doesn’t opt in.
Merck ditches vibostolimab and favezelimab following huge pivotal programmes.
Reports of Arc-10's failure are greatly exaggerated, the company argues.
Failed trials of vibostolimab and domvanalimab will be unveiled at SITC late-breakers.
There’s little to distinguish the two HIF2α inhibitors in kidney cancer.
Aktis scores a plenary, as do Tyra’s FGFR3 inhibitor and Arcus’s HIF-2α contender.